Thermo Fisher Scientific Inc. has announced a strategic collaboration with SHL Medical, a leading provider of advanced drug delivery systems, alongside an expansion of sterile fill-finish and autoinjector final assembly capacity at its Ridgefield, NJ site.
Together, these investments establish a fully integrated US-based offering spanning sterile manufacturing, device assembly and commercial packaging for drug-device combination products.
Demand for patient-centric, self-administered injectable therapies continues to grow across multiple therapeutic areas including autoimmune diseases, inflammatory conditions, and other chronic diseases. To meet this need, Thermo Fisher is expanding pre-filled syringe (PFS) fill-finish and device assembly in Ridgefield. In parallel, its strategic partnership with SHL Medical enables integration of SHL Medical's Molly® autoinjector platform with Thermo Fisher’s sterile manufacturing network, creating a seamless, end-to-end solution from drug product to finished device.
Thermo Fisher acquired the Ridgefield facility from Sanofi in September 2025 as part of its strategy to strengthen its US manufacturing footprint. The site is being developed as a premier North American hub for integrated sterile fill-finish, autoinjector final assembly and packaging, increasing domestic capacity to support customer supply chains.
Under the strategic, non-exclusive collaboration, Thermo Fisher and SHL Medical will provide integrated support for SHL Medical’s Molly® autoinjector platform at the Ridgefield site, including device final assembly, packaging and distribution. The collaboration is designed to simplify development and manufacturing for pharmaceutical and biotechnology customers, supporting a streamlined path from drug product manufacturing through commercialisation.
